MIM
ORGO icon

MetLife Investment Management’s Organogenesis Holdings ORGO Stock Holding History

MetLife Investment Management’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3K Buy
39,222
+23,737
+153% +$58K ﹤0.01% 2788
2026
Q1 		$36.7K Sell
15,485
-14,948
-49% -$51.8K ﹤0.01% 2702
2025
Q4 		$158K Sell
30,433
-8,965
-23% -$43.4K ﹤0.01% 2392
2025
Q3 		$166K Sell
39,398
-2,402
-6% -$11.2K ﹤0.01% 2418
2025
Q2 		$153K Buy
41,800
+6,677
+19% +$24.9K ﹤0.01% 2327
2025
Q1 		$152K Sell
35,123
-1,470
-4% -$5.93K ﹤0.01% 2333
2024
Q4 		$117K Buy
36,593
+9,465
+35% +$31.8K ﹤0.01% 2553
2024
Q3 		$77.6K Sell
27,128
-14,727
-35% -$41.3K ﹤0.01% 2701
2024
Q2 		$117K Buy
41,855
+5,020
+14% +$13.5K ﹤0.01% 2529
2024
Q1 		$105K Sell
36,835
-1,190
-3% -$4.04K ﹤0.01% 2511
2023
Q4 		$156K Hold
38,025
– – ﹤0.01% 2375
2023
Q3 		$121K Hold
38,025
– – ﹤0.01% 2482
2023
Q2 		$126K Hold
38,025
– – ﹤0.01% 2544
2023
Q1 		$81K Buy
38,025
+15,356
+68% +$37.9K ﹤0.01% 2632
2022
Q4 		$61K Sell
22,669
-15,279
-40% -$44.6K ﹤0.01% 2733
2022
Q3 		$123K Buy
37,948
+16,513
+77% +$74.6K ﹤0.01% 2576
2022
Q2 		$105K Sell
21,435
-18,204
-46% -$112K ﹤0.01% 2695
2022
Q1 		$302K Buy
39,639
+24,906
+169% +$193K ﹤0.01% 2093
2021
Q4 		$136K Hold
14,733
– – ﹤0.01% 2286
2021
Q3 		$210K Hold
14,733
– – ﹤0.01% 2071
2021
Q2 		$245K Buy
14,733
+4,126
+39% +$76.9K ﹤0.01% 2026
2021
Q1 		$193K Buy
+10,607
New +$144K ﹤0.01% 2069

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MetLife Investment Management's ORGO Position: Q2 2026 in Review

MetLife Investment Management increased its Organogenesis Holdings (ORGO) stake by 153% in Q2 2026, buying an estimated $58K and bringing the position to 39,222 shares worth $95.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

MetLife Investment Management first reported a position in ORGO in Q1 2021 and has held it in 22 quarters since. The position peaked at $302K in Q1 2022. 134 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • MetLife Investment Management held 39,222 shares of Organogenesis Holdings worth $95.3K as of Q2 2026.
  • MetLife Investment Management bought 23,737 Organogenesis Holdings shares in Q2 2026, an estimated $58K.
  • Organogenesis Holdings made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2788 holding.
  • MetLife Investment Management first reported a position in Organogenesis Holdings in Q1 2021 and has held it in 22 quarters since.
  • MetLife Investment Management's Organogenesis Holdings position peaked at $302K in Q1 2022.
  • 134 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.